A Study to Investigate the Effects of AZD0901 Monotherapy in Adult Participants With 2L+ Advanced or Metastatic Gastric or GEJ Adenocarcinoma Expressing CLDN18.2
← catalyst calendarNCT07143604 · readout in 39 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
33actual
Sites
13
Country
Russia
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-08-29 | actual | When the study began enrolling |
| Primary completion | 2026-09-28 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-09-28 | estimated | The whole study's end, after follow-up |
| First posted | 2025-08-27 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Gastric Cancer
- Gastroesophageal Junction Cancer
Intervention
- Drug: AZD0901 — also filed as Sonesitatug Vedotin
Primary outcome
what the primary-completion date above is the date OFObjective Response Rate (ORR)
measured At month 6 after date of first dose
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed